Dr. Lynch on the Goals of Bristol-Myers Squibb

Thomas Lynch, Jr, MD
Published: Friday, Jul 27, 2018



Thomas Lynch, Jr, MD, Vice President and Chief Scientific Officer at Bristol-Myers Squibb, discusses the goals of Bristol-Myers Squibb.

Lynch believes that physicians are motivated by 2 things—the desire to help patients and the sense of mission of the hospital, doctors, and nurses. These caregivers are working together for a common cause. Bristol-Myers Squibb embodies that same sense of a common cause, explains Lynch. The common cause centers around the idea of scientists, regulatory agencies, and clinical trial developers working together to create better medicine, states Lynch.

Over the next several years, Lynch says that his goals are to improve the ability of these medicines to make a difference in improving the cure rate for cancers and help people live longer, he says.
 
SELECTED
LANGUAGE


Thomas Lynch, Jr, MD, Vice President and Chief Scientific Officer at Bristol-Myers Squibb, discusses the goals of Bristol-Myers Squibb.

Lynch believes that physicians are motivated by 2 things—the desire to help patients and the sense of mission of the hospital, doctors, and nurses. These caregivers are working together for a common cause. Bristol-Myers Squibb embodies that same sense of a common cause, explains Lynch. The common cause centers around the idea of scientists, regulatory agencies, and clinical trial developers working together to create better medicine, states Lynch.

Over the next several years, Lynch says that his goals are to improve the ability of these medicines to make a difference in improving the cure rate for cancers and help people live longer, he says.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x